Murine model of cancer gene therapy

Area of Science:

• Immunology
• Gene Therapy
• Oncology

Background:

• Adenovirus-mediated gene therapy is a promising approach for cancer treatment.
• Understanding the immune response to adenovirus vectors is crucial for optimizing gene therapy efficacy.
• Developing effective anti-cancer immunity is a key challenge in oncology.

Purpose of the Study:

• To investigate the induction of anti-adenoviral immunity following adenovirus gene therapy.
• To determine if adenovirus-induced immunity can lead to the rejection of tumor cells.
• To explore the potential of adenovirus gene therapy in establishing long-term tumor-specific immunity.

Main Methods:

• Adenovirus carrying LacZ (AxCALacZ) gene was administered intraperitoneally to DBA/2 mice.
• P815 tumor cells, infected with AxCALacZ, were inoculated into immune mice.
• Cytotoxicity assays were performed to assess T cell activity against tumor cells.
• Parental P815 tumor cells were inoculated to evaluate cross-immunity.

Main Results:

• Mice immunized with AxCALacZ rejected P815 tumor cells infected with the same adenovirus.
• Peritoneal T cells from immune mice exhibited significant killing activity against adenovirus-infected tumor cells.
• All mice demonstrated rejection of parental P815 tumor cells, indicating developed tumor-specific immunity.
• Long-term survival was observed in mice that rejected tumor cells.

Conclusions:

• Adenovirus gene therapy effectively induces anti-adenoviral immunity in a murine model.
• This induced immunity confers protection against tumors infected with the adenovirus vector.
• The study demonstrates the development of P815-specific tumor immunity, suggesting potential for broader anti-cancer applications.